Ruxolitinib-Associated Karyomegalic Interstitial Nephritis without FAN1 Mutation: Expanding the Etiology to Janus-Associated Kinase Inhibitors
Nephron · 15.05.2026 · 1-6
DOI: 10.1159/000552531 ↗Kurz gefasst
Fallbericht in der Zeitschrift Nephron, online erschienen am 15.05.2026. Verfasst von Sara Aldana und 6 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Nephritis, Interstitial, Pyrazoles, Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Karyomegalic interstitial nephritis (KIN) is a rare entity characterized by enlarged, hyperchromatic, and pleomorphic tubular epithelial nuclei within the setting of chronic tubulointerstitial nephritis. Although classically associated with hereditary mutations in the FAN1 gene, acquired forms have been described, generally linked to the use of cytotoxic or immunomodulatory agents that presumably act as a “second hit.” Case Presentation: We report the case of a 53-year-old male with a history of acute myeloid leukemia in complete remission after allogeneic stem cell transplantation, who developed acute kidney injury following prolonged treatment with ruxolitinib for graft-versus-host disease. Renal biopsy revealed characteristic features of KIN, while genetic testing was negative for FAN1 mutations. After ruxolitinib withdrawal, progressive improvement in renal function was observed.
Conclusion
This represents the first reported case of KIN associated with JAK inhibitors. We propose that ruxolitinib may induce DNA repair defects in the absence of known genetic predisposition, highlighting the need to consider this entity in patients with unexplained chronic interstitial nephropathy under complex immunomodulatory therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nephrology Department, Hospital Universitario La Paz, Madrid, Spain.
- Pathology Department, Hospital Universitario La Paz, Madrid, Spain.
- Hematology Department, Hospital Universitario La Paz, Madrid, Spain.
- Instituto de Genética Médica y Molecular (INGEMM)-IdiPAZ, Hospital Universitario La Paz, Madrid, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), ISCIII, Madrid, Spain.
- Nephrology Department, Hospital Universitario La Paz, Madrid, Spain, amirshabaka@hotmail.com.
Zitieren
APA
Aldana, S., García-Fernández, E., Humala, K., Nevado, J., Azores-Moreno, J., Fernández-Juárez, G., & Shabaka, A. (2026). Ruxolitinib-Associated Karyomegalic Interstitial Nephritis without FAN1 Mutation: Expanding the Etiology to Janus-Associated Kinase Inhibitors. Nephron, 1-6. https://doi.org/10.1159/000552531
Vancouver
Aldana S, García-Fernández E, Humala K, Nevado J, Azores-Moreno J, Fernández-Juárez G, et al. Ruxolitinib-Associated Karyomegalic Interstitial Nephritis without FAN1 Mutation: Expanding the Etiology to Janus-Associated Kinase Inhibitors. Nephron. 2026:1-6. doi:10.1159/000552531
BibTeX
@article{Aldana2026,
author = {Aldana, Sara and García-Fernández, Eugenia and Humala, Karem and Nevado, Julián and Azores-Moreno, Javier and Fernández-Juárez, Gema and Shabaka, Amir},
title = {Ruxolitinib-Associated Karyomegalic Interstitial Nephritis without FAN1 Mutation: Expanding the Etiology to Janus-Associated Kinase Inhibitors},
journal = {Nephron},
year = {2026},
pages = {1--6},
doi = {10.1159/000552531}
}
EUVIMED